GREAT-2 is a clinical trial to test a new treatment for bronchiectasis.

People with bronchiectasis frequently get chest infections which are difficult to treat. Approximately one third of people with bronchiectasis become infected with a bacteria called Pseudomonas aeruginosa (P. aeruginosa).

The purpose of this trial is to test whether an intravenous infusion drip containing a new drug called Gremubamab can reduce the amount of infection with P. aeruginosa.

The trial is being Sponsored by the University of Dundee & NHS Tayside and is being managed by Tayside Clinical Trials Unit.